Aliskiren in Patients With Idiopathic Membranous Nephropathy
Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The goal of this proposal is to conduct a pilot study to access the antiproteinuric effect of
aliskiren in patients with idiopathic membranous nephropathy. Patients will be treated for 3
months with aliskiren aiming to achieve the maximum tolerated dose and blood pressure (>100
but <125 mmHg systolic BP >75% of the readings).